Electrochemical glucose test strips, such as those used in the OneTouch® Ultra® whole blood testing kit, which is available from LifeScan, Inc., are designed to measure the concentration of glucose in a blood sample from patients with diabetes. The measurement of glucose is based upon the specific oxidation of glucose by the enzyme glucose oxidase (GO). The reactions which may occur in a glucose test strip are summarized below in Equations 1 and 2.
Glucose+GO(ox)→Gluconic Acid+GO(red) Eq. 1
GO(red)+2Fe(CN)63−→GO(ox)+2Fe(CN)64− Eq. 2
As illustrated in Equation 1, glucose is oxidized to gluconic acid by the oxidized form of glucose oxidase (GO(ox)). It should be noted that GO(ox) may also be referred to as an “oxidized enzyme.” During the reaction in Equation 1, the oxidized enzyme GO(ox) is converted to its reduced state which is denoted as GO(red) (i.e., “reduced enzyme”). Next, the reduced enzyme GO(red) is re-oxidized back to GO(ox) by reaction with Fe(CN)63− (referred to as either the oxidized mediator or ferricyanide) as illustrated in Equation 2. During the re-generation of GO(red) back to its oxidized state GO(ox), Fe(CN)63− is reduced to Fe(CN)64− (referred to as either reduced mediator or ferrocyanide).
When the reactions set forth above are conducted with a test voltage applied between two electrodes, a test current may be created by the electrochemical re-oxidation of the reduced mediator at the electrode surface. Thus, since, in an ideal environment, the amount of ferrocyanide created during the chemical reaction described above is directly proportional to the amount of glucose in the sample positioned between the electrodes, the test current generated would be proportional to the glucose content of the sample. A mediator, such as ferricyanide, is a compound that accepts electrons from an enzyme such as glucose oxidase and then donates the electrons to an electrode. As the concentration of glucose in the sample increases, the amount of reduced mediator formed also increases; hence, there is a direct relationship between the test current, resulting from the re-oxidation of reduced mediator, and glucose concentration. In particular, the transfer of electrons across the electrical interface results in the flow of a test current (2 moles of electrons for every mole of glucose that is oxidized). The test current resulting from the introduction of glucose may, therefore, be referred to as a glucose current.
Because it can be very important to know the concentration of glucose in blood, particularly in people with diabetes, test meters have been developed using the principals set forth above to enable the average person to sample and test their blood for determining their glucose concentration at any given time. The glucose current generated is detected by the test meter and converted into a glucose concentration reading using an algorithm that relates the test current to a glucose concentration via a simple mathematical formula. In general, the test meters work in conjunction with a disposable test strip that includes a sample receiving chamber and at least two electrodes disposed within the sample receiving chamber in addition to the enzyme (e.g. glucose oxidase) and the mediator (e.g. ferricyanide). In use, the user pricks their finger or other convenient site to induce bleeding and introduces a blood sample to the sample receiving chamber, thus starting the chemical reaction set forth above.
In electrochemical terms, the function of the meter is two fold. Firstly, it provides a polarizing voltage (approximately 400 mV in the case of OneTouch® Ultra®) that polarizes the electrical interface and allows current flow at the carbon working electrode surface. Secondly, it measures the current that flows in the external circuit between the anode (working electrode) and the cathode (reference electrode). The test meter may, therefore be considered to be a simple electrochemical system that operates in a two-electrode mode although, in practice, third and, even fourth electrodes may be used to facilitate the measurement of glucose and/or perform other functions in the test meter.
As previously described, the amount of reduced mediator should be proportional to the glucose concentration present in a physiological fluid based on the reactions described in Equation 1 & 2. Under certain circumstances, oxidized mediators such as, for example, ferricyanide can be converted to ferrocyanide (reduced mediator) in the presence of a humid environment. The generation of reduced mediator by non-glucose dependent reactions may cause a falsely elevated glucose concentration to be measured which, in turn, affects the assay's accuracy.
The presence of interfering compounds may also cause the test current to be falsely elevated because the interfering compound may become oxidized at the working electrode. Additionally, the oxidized mediator may become reduced by the interfering compound where the resulting reduced mediator can become oxidized at the working electrode. One strategy for decreasing the effects of interfering compounds is to use a relatively low test voltage between the working electrode and reference electrode. In order to employ a lower test voltage, the reagent formulation requires the mediator to have a lower redox voltage.
As such, applicants recognize that there is a great need for using mediators which do not convert to the reduced state in the presence of humidity and have a relatively low redox voltage. Further, such mediators need to be incorporated into a reagent formulation that can be easily coated onto a test strip in a robust manner enabling accurate and precise glucose measurements.
In one embodiment, a test strip is provided which is capable of measuring an analyte. The test strip may include a working electrode and a reference electrode where the reagent formulation is disposed on the working electrode. The reagent formulation may be coated onto the test strip. The reagent formulation includes an enzyme, a ruthenium hexamine mediator, and a solution for dissolving the enzyme and the ruthenium hexamine mediator. The ruthenium hexamine has a concentration range from about 15% to about 20% (weight of mediator/volume) of solution. The enzyme may be either glucose oxidase and glucose dehydrogenase. When using glucose oxidase, the enzyme activity per unit volume may range from about 1500 units/mL to about 8000 units/mL. The solution for dissolving the enzyme may be a buffer such as, for example, phosphate, citrate, or citraconate. When using phosphate buffer, the pH may be about 7.
In another embodiment, the reagent formulation may further include a filler having hydrophilic and hydrophobic domains. In one embodiment, the filler may be a silica such as for example Cab-o-Sil TS 610. The formulation may be disposed on the working electrode using a process of screen printing. The screen may have a frame which secures a plurality of interwoven threads. The plurality of interwoven threads may form a plurality of open rectangular spaces for allowing the reagent formulation to pass therethrough. The plurality of interwoven threads may have a thread spacing and a thread diameter. The thread spacing may range from about 90 threads per centimeter to about 120 threads per centimeter. The thread diameter may range from about 30 microns to about 50 microns.
In another aspect, a test strip includes a substrate, two electrodes and a reagent. The generally planar substrate extends from a first end to a second end. The first and second electrodes are disposed on the substrate proximate one of the first and second ends with a reagent layer disposed thereon. The reagent layer has ruthenium hexamine trichloride in a buffer solution with a concentration range from about 15% to about 20% (weight/volume) such that the test strip shows essentially no increase in bias to reference when a blood sample is tested at about 400 millivolts after storage for seven days at 40 degrees Celsius at 75% relative humidity.
In a further aspect, a test strip is provided that includes a substrate, two electrodes and a reagent. The generally planar substrate extends from a first end to a second end. The first and second electrodes are disposed on the substrate proximate one of the first and second ends with a reagent layer disposed thereon. The reagent layer has a reagent layer with ruthenium hexamine Trichloride in a buffer solution with a concentration range from about 15% to about 20% (weight/volume) such that the test strip shows essentially no increase in bias to reference when tested at about 400 millivolts with blood glucose sample of about 70 mg/dL with uric acid concentration of about 0 mg/dL to about 20 mg/dL.
In a further aspect, a test strip is provided that includes a substrate, two electrodes and a reagent. The generally planar substrate extends from a first end to a second end. The first and second electrodes are disposed on the substrate proximate one of the first and second ends with a reagent layer disposed thereon. The reagent layer has a reagent layer with an enzyme and ruthenium hexamine trichloride in a buffer solution with a concentration range from about 15% to about 20% (weight/volume) such that the test strip shows essentially no increase in bias to reference when tested at about 400 millivolts with blood glucose sample of about 70 mg/dL with gentisic acid concentration from about 0 mg/dL to about 50 mg/dL.
The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
a is a graph illustrating the application of an applied test voltage, from the test meter of
b is a graph illustrating an alternative embodiment for applying test voltages and an open-circuit time interval, from the test meter of
c is an expanded view of the graph of
Embodiments of the present invention are directed to a reagent formulation for use in electrochemical test strips. In particular, the embodiments include the use of ruthenium hexamine as a mediator to enable the manufacture of test strips which have increased stability under high humidity environmental conditions and/or also have decreased oxidation of interfering compounds. In an embodiment, a reagent formulation is described which may be easily coated onto a test strip in a robust manner enabling accurate and precise glucose measurements.
The fully assembled test strip 100, as shown in
For test strip 100, as illustrated in
In
Reagent layer 22 may be disposed on a portion of conductive layer 50, substrate 5, and insulation layer 16 as illustrated in
Examples of enzymes suitable for use in this invention may include either glucose oxidase or glucose dehydrogenase. More specifically, the glucose dehydrogenase may have a pyrrylo-quinoline quinone co-factor (abbreviated as PQQ or may be referred to its common name which is methoxatin). Examples of mediator suitable for use in this invention may include either ferricyanide or ruthenium hexamine trichloride ([RuIII(NH3)6]Cl3 and may also be simply referred to as ruthenium hexamine). During the reactions as illustrated in Equations 1 and 2, a proportional amount of reduced mediator can be generated that is electrochemically measured for calculating a glucose concentration. Examples of reagent formulations or inks suitable for use in the embodiments can be found in U.S. Pat. Nos. 5,708,247 6,046,051, and 6,241,862; U.S. Pre-Grant Publication No. 20030217918A1; published international applications WO01/67099 and WO01/73124.
Reagent layer 22 may be formed from an enzyme ink or formulation, which is disposed onto a conductive layer and dried. An enzyme ink or formulation typically contains a liquid, such as a buffer, for dispersing and/or dissolving materials used for the electrochemical detection of an analyte such as glucose. Buffers which may be suitable for the formulation can be phosphate, citrate and citraconate.
In an embodiment, the formulation may include a 200 mM phosphate buffer having a pH of about 7 and a ruthenium hexamine mediator concentration ranging from about 5% and greater, preferably ranging from about 10% and greater, and yet more preferably ranging from about 15% to about 20% (percentage based on weight of mediator/volume of buffer). The pH of around 7 was chosen because glucose oxidase has a sufficiently high activity at this pH when using ruthenium hexamine as a mediator. The upper range for the ruthenium hexamine concentration may be selected based on its solubility. When the enzyme ink is formulated to have greater than a 20% ruthenium hexamine concentration, solid particles of ruthenium hexamine may be present in reagent layer 22 which do not dissolve during testing. The presence of undissolved ruthenium hexamine may cause a decrease in the test strip-to-test strip precision. When the enzyme ink is formulated to have less than a 15% ruthenium hexamine concentration, the magnitude of the test current values may decrease with the concentration of ruthenium hexamine. In general, it is undesirable for the magnitude of the test current values to be dependent on the concentration of ruthenium hexamine because small changes in ruthenium hexamine concentration will cause variability in the test current values and, in turn, the strip lot-to-strip lot variability.
In an embodiment, the formulation may have an enzyme activity ranging from about 1500 units/mL to about 8000 units/mL. The enzyme activity range may be selected so that the glucose current does not depend on the level of enzyme activity in the formulation so long as the enzyme activity level is within the above stated range. The enzyme activity should be sufficiently large to ensure that the resulting glucose current will not be dependent on small variations in the enzyme activity. For instance, the glucose current will depend on the amount of enzyme activity in the formulation if the enzyme activity is less than 1500 units/mL. On the other hand, for enzyme activity levels greater than 8000 units/mL, solubility issues may arise where the glucose oxidase cannot be sufficiently dissolved in the formulation. Glucose oxidase may be commercially available from Biozyme Laboratories International Limited (San Diego, Calif., U.S.A.). The glucose oxidase may have an enzyme activity of about 250 units/mg using where the enzyme activity units are based on an o-dianisidine assay at pH 7 and 25° C.
An enzyme ink which contains a filler having both hydrophobic and hydrophilic domains may be disposed onto the working electrode using a screen printing process. An example of a filler may be a silica such as, for example, Cab-o-Sil TS 610 which is commercially available from Cabot Inc., Boston, Mass. Typically, a screen may be in the form of a rectangular frame which secures a plurality of interwoven threads. The plurality of interwoven threads form a plurality of open rectangular spaces for allowing enzyme ink to pass therethrough. The density and the size of the open spaces influence the amount of enzyme ink which becomes deposited on the conductive layer. Characteristics of the interwoven threads which influence the deposition of the enzyme ink are thread spacing and thread diameter. The thread spacing may range from about 90 threads per centimeter to about 120 threads per centimeter. The thread diameter may range from about 30 microns to about 50 microns. More specifically, in an embodiment, a screen suitable for screen printing an enzyme ink having ruthenium hexamine and glucose oxidase may have a thread spacing of about 120 threads per centimeter and a thread diameter of about 34 microns.
For test strip 100, adhesive layer 60 includes first adhesive pad 24, second adhesive pad 26, and third adhesive pad 28 as illustrated in
Hydrophilic layer 70 includes a distal hydrophilic portion 32 and proximal hydrophilic portion 34. Hydrophilic layer 70 may be a polyester having one hydrophilic surface such as an anti-fog coating which is commercially available from 3M.
For test strip 100, top layer 80 includes a clear portion 36 and opaque portion 38 as illustrated in
a is a chart showing a test voltage that would be applied by test meter 200 to test strip 100 for a test time interval tT which starts when physiological fluid is detected by test strip 100. In
In an alternative embodiment, a test voltage waveform can be applied that includes an open-circuit time interval after fluid is detected in sample receiving chamber 92. For example, the test voltage as shown in
In general, it is desirable to use a test voltage which is more positive than a redox voltage of the mediator used in the test strip. In particular, the test voltage should exceed the redox voltage by an amount sufficient to ensure that the resulting test current will not be dependent on small variations in the test voltage. Note that a redox voltage describes a mediator's intrinsic affinity to accept or donate electrons when sufficiently close to an electrode having a nominal voltage. When a test voltage is sufficiently positive with respect to the mediator's redox voltage, the mediator will be rapidly oxidized. In fact, the mediator will be oxidized so quickly at a sufficiently positive test voltage (i.e., limiting test voltage) that the test current magnitude will be limited by the diffusion of the mediator to the electrode surface (i.e., limiting test current). For an embodiment where first working electrode 12 is a carbon ink and the mediator is ferricyanide, a test voltage of about +400 mV may be sufficient to act as a limiting test voltage. For an embodiment where first working electrode 12 is a carbon ink and the mediator is RuIII(NH3)6, a test voltage of about +250 mV may be sufficient to act as a limiting test voltage. It will be apparent to one skilled in the art that other mediator and electrode material combinations will require different limiting test voltages.
A test meter that is designed to apply a limiting test voltage can have some variation in the applied test voltage without affecting the magnitude of the limiting test current. It is desirable for a test meter to apply a limiting test voltage because the test meter can be constructed with relatively inexpensive electronic components because it is not necessary to tightly control the test voltage. In summary, a test meter which applies a limiting test voltage can robustly measure a glucose concentration in an accurate and precise manner using low cost components.
To produce sufficiently accurate and precise glucose concentration, test strip 100 should have a sufficiently reproducible and well defined electroactive area for first working electrode 12 and second working electrode 14. The magnitude of the test current is directly proportional to the area of one of the working electrodes. For instance, if the variation in the area of first working electrode 12 was high from one test strip to another, then the variation observed in the measured glucose concentrations will also be high when testing multiple test strips. Thus, it is important that the variation for first working electrode 12 and second working electrode 14 be relatively small so that the variation in the measured glucose concentration can, in turn, also be relatively small.
The area of first working electrode 12 and second working electrode 14, as shown in
One strategy for designing test strips which have smaller sample volumes is to decrease the area of the first and second working electrode. However, as first and second working electrode and second working electrode become smaller, non-idealities in the screen printing process may start to significantly affect the precision of the working electrodes. For instance, variable stretching of a screen by a squeegee may affect the size of a working electrode. Additionally, a screen typically has a plurality of rectangular openings for deposing either a conductive layer or an insulation layer. The plurality of rectangular opening may cause an edge of either the conductive layer or insulation layer to be jagged especially when the size of the working electrode is comparable to the size of the rectangular opening. In the prior art embodiment as illustrated in
In an embodiment, a test strip may be manufactured using a process of laser ablation for improving the accuracy and precision of the electroactive area of the first and second working electrode. The process of laser ablation on a conductive layer allows the edge definition of the electrode area to be better controlled than with other processes such as screen printing. In addition, the process of laser ablation may be used to substantially define the electrode area without the need of an insulation layer.
Although various embodiments described herein are particularly adapted to the measurement of a glucose concentration in blood, it will be apparent to those skilled in the art that the test strip described herein may be adapted to enable an improved precision for the electrochemical measurement of other analytes. Examples of other analytes that may be measured with the test strip embodiments are lactate, ethanol, cholesterol, amino acids, choline, hemoglobin, and fructosamine in blood.
The reagent layer was formulated as an enzyme ink suitable for screen printing as follows. 100 ml of 200 mM aqueous phosphate buffer was adjusted to pH 7. A mixture was formed by adding 5 g of hydroxyethyl cellulose (HEC), 1 g of poly(vinyl pyrrolidone vinyl acetate) (PVP-VA S-630), 0.5 ml of DC 1500 Dow Corning antifoam to 100 mL of phosphate buffer and mixed by homogenization. The mixture was allowed to stand overnight to allow air bubbles to disperse and then used as a stock solution for the formulation of the enzyme ink. Next, 7.5 grams of Cab-o-Sil TS610 was gradually added by hand to the mixture until about ⅘ of the total amount of Cab-o-Sil TS610 had been added. The remainder Cab-o-Sil TS610 was added with mixing by homogenization. The mixture was then rolled for 12 hours. About 18 g of ruthenium hexamine ([RuIII(NH3)6]Cl3) was then added and mixed by homogenization until dissolved. Finally, 2.8 g of glucose oxidase enzyme preparation (250 Units/mg) was added and then thoroughly mixed into the solution. The resulting formulation was ready for printing, or could be stored with refrigeration.
A first batch of test strips 100 was prepared using a ruthenium based reagent formulation as described in Example 1. A second batch of test strips 100 was prepared with a reagent formulation using a ferricyanide mediator instead of ruthenium hexamine in a manner similar to Example 1. A portion of the first and second batch of test strips 100 were stored at room temperature in a desiccated environment for 7 days. Another portion of the first and second batch of test strips 100 were stored at 40° C. in a 70% relative humidity environment for 7 days.
The first and second batch of test strips were tested in a test meter using a test voltage at +400 mV. Blood samples were tested which had a glucose concentration ranging from about 70 mg/dL to about 600 mg/dL.
The first and second batch of test strips (as described in Example 2) were tested in a test meter using a test voltage at +400 mV. Blood samples were tested which had a glucose concentration of about 70 mg/dL and a uric acid concentration ranging from about 0 mg/dL to about 20 mg/dL.
For the second batch of test strips as illustrated by open triangles in
For the first batch of test strips as illustrated by filled in diamonds in
The first and second batch of test strips (as described in Example 2) were tested in a test meter using a test voltage at +400 mV. Blood samples were tested which had a glucose concentration of about 70 mg/dL and a gentisic acid concentration ranging from about 0 mg/dL to about 50 mg/dL.
For the second batch of test strips as illustrated by open triangles in
For the first batch of test strips as illustrated by filled in diamonds in
While the invention has been described in terms of particular variations and illustrative figures, those of ordinary skill in the art will recognize that the invention is not limited to the variations or figures described. In addition, where methods and steps described above indicate certain events occurring in certain order, it is intended that certain steps do not have to be performed in the order described but in any order as long as the steps allow the embodiments to function for their intended purposes. Therefore, to the extent there are variations of the invention, which are within the spirit of the disclosure or equivalent to the inventions found in the claims, it is the intent that this patent will cover those variations as well.
This application claims the benefits of priority under 35 U.S.C. § 119 from provisional application Ser. No. 60/850,221 filed on Oct. 5, 2006, entitled: “A REAGENT FORMULATION USING A RUTHENIUM BASED MEDIATOR FOR ELECTROCHEMICAL TEST STRIPS,” which application is incorporated by reference in its entirety herein.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/GB2007/003772 | 10/5/2007 | WO | 00 | 7/1/2009 |
Number | Date | Country | |
---|---|---|---|
60850221 | Oct 2006 | US |